Mesoblast ADRs Rise 22%, Company Joining Nasdaq Biotechnology Index

Dow Jones

2024-12-19

By Stephen Nakrosis

The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the Food and Drug Administration approved its Ryoncil as a treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.

Also on Wednesday, the company said it will be added to the Nasdaq Biotechnology Index, effective Dec. 23.

After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25.

Mesoblast said it develops allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 18, 2024 19:11 ET (00:11 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492166865"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492166865\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492166865?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 07:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492166865","market":"sh","top_or_hot":-1,"title":"Mesoblast ADRs Rise 22%, Company Joining Nasdaq Biotechnology Index","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the Food and Drug Administration approved its Ryoncil as a treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. \n</p>\n<p>\n  Also on Wednesday, the company said it will be added to the Nasdaq Biotechnology Index, effective Dec. 23. \n</p>\n<p>\n  After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25. \n</p>\n<p>\n  Mesoblast said it develops allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2024 19:11 ET (00:11 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast ADRs Rise 22%, Company Joining Nasdaq Biotechnology Index</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast ADRs Rise 22%, Company Joining Nasdaq Biotechnology Index\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-19 07:20</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the Food and Drug Administration approved its Ryoncil as a treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. \n</p>\n<p>\n  Also on Wednesday, the company said it will be added to the Nasdaq Biotechnology Index, effective Dec. 23. \n</p>\n<p>\n  After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25. \n</p>\n<p>\n  Mesoblast said it develops allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2024 19:11 ET (00:11 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492166865","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492166865","pubTimestamp":1734564000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the company will be added to the Nasdaq Biotechnology Index, effective Dec. 23.After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25.Mesoblast said it develops allogeneic  cellular medicines for the treatment of severe and life-threatening inflammatory conditions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK7508":"医药生物股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NVIW.SI":"NVDA 3xLongSG261006","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","MSB.AU":"MESOBLAST LTD","SQQQ":"纳指三倍做空ETF","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK7067":"生物科技","TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","NDAQ":"纳斯达克OMX交易所","QLD":"纳指两倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","USJW.SI":"ALPHAB 3xLongSG261006","BK4588":"碎股","MESO":"Mesoblast Limited","BK7501":"新冠治疗股","TSYW.SI":"TESLA 3xLongSG261006","BK4112":"金融交易所和数据","USAW.SI":"AMZN 3xLongSG261006"},"translate_title":"Mesoblast ADR上涨22%，公司加入纳斯达克生物技术指数","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NQmain":1,"NDAQ":1,"MESO":1,".IXIC":1,"MSB.AU":0.9,"USJW.SI":0.6,"USAW.SI":0.6,"TSYW.SI":0.6,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NVIW.SI":0.6,"MNQmain":0.6},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the Food and Drug Administration approved its Ryoncil as a treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. \n\n\n  Also on Wednesday, the company said it will be added to the Nasdaq Biotechnology Index, effective Dec. 23. \n\n\n  After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25. \n\n\n  Mesoblast said it develops allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2024 19:11 ET (00:11 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0}}}